Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor

Craig R. Smith, Andrés Jaramillo, Kim Lu, Toru Higuchi, Zahid Kaleem, T. Mohanakumar

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background. Inflammatory cytokines play an important role in the development of experimental obliterative airway disease (OAD) after transplantation. To further determine the immunologic mechanisms associated with OAD development, we used a murine tracheal transplant model in which a single mismatched HLA-A2 transgenic molecule is indirectly recognized by the recipient CD4+ T cells and then determined whether neutralization of several inflammatory cytokines affected the development of OAD. Methods. Tracheas from HLA-A2+ C57BL/6 mice were heterotopically transplanted into C57BL/6 mice. Recipients were treated with neutralizing antibodies against tumor necrosis factor (TNF), interferon-γ (IFN-γ), or interleukin-1 (IL-1). Allograft histology as well as anti HLA-A2 antibody development and T cell proliferative responses were determined at days +5, +15, +28, and +60. Results. Allografts in untreated and anti-IFN-γ-treated recipients demonstrated full development of OAD by day +28. Allografts in anti-TNF-treated recipients showed no evidence of OAD, even at day +60. Allografts in anti-IL-1-treated recipients showed airway epithelium changes by day +28 but minimal evidence of OAD by day +60. Spleen cells from untreated and anti-IFN-γ treated recipients showed significantly higher proliferative responses to HLA-A2+ cells, compared with syngeneic recipients (negative controls). In contrast, anti-TNF and anti-IL-1-treated recipients showed significantly lower proliferative responses to HLA-A2+ cells, compared with untreated recipients. Development of anti HLA-A2 antibodies was detected in all recipients by day +15, with the exception of those treated with anti-TNF. Conclusion. Among the inflammatory cytokines, TNF seems to play a crucial role in the immunopathology of OAD developed after transplantation.

Original languageEnglish (US)
Pages (from-to)1512-1518
Number of pages7
JournalTransplantation
Volume72
Issue number9
StatePublished - Nov 15 2001
Externally publishedYes

Fingerprint

HLA-A2 Antigen
Allografts
Tumor Necrosis Factor-alpha
Interleukin-1
Interferons
Cytokines
Inbred C57BL Mouse
Transplantation
T-Lymphocytes
Antibodies
Trachea
Neutralizing Antibodies
Histology
Spleen
Epithelium
Transplants

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Smith, C. R., Jaramillo, A., Lu, K., Higuchi, T., Kaleem, Z., & Mohanakumar, T. (2001). Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. Transplantation, 72(9), 1512-1518.

Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. / Smith, Craig R.; Jaramillo, Andrés; Lu, Kim; Higuchi, Toru; Kaleem, Zahid; Mohanakumar, T.

In: Transplantation, Vol. 72, No. 9, 15.11.2001, p. 1512-1518.

Research output: Contribution to journalArticle

Smith, CR, Jaramillo, A, Lu, K, Higuchi, T, Kaleem, Z & Mohanakumar, T 2001, 'Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor', Transplantation, vol. 72, no. 9, pp. 1512-1518.
Smith, Craig R. ; Jaramillo, Andrés ; Lu, Kim ; Higuchi, Toru ; Kaleem, Zahid ; Mohanakumar, T. / Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. In: Transplantation. 2001 ; Vol. 72, No. 9. pp. 1512-1518.
@article{a803c386a24b4721991d21fc33a519b2,
title = "Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor",
abstract = "Background. Inflammatory cytokines play an important role in the development of experimental obliterative airway disease (OAD) after transplantation. To further determine the immunologic mechanisms associated with OAD development, we used a murine tracheal transplant model in which a single mismatched HLA-A2 transgenic molecule is indirectly recognized by the recipient CD4+ T cells and then determined whether neutralization of several inflammatory cytokines affected the development of OAD. Methods. Tracheas from HLA-A2+ C57BL/6 mice were heterotopically transplanted into C57BL/6 mice. Recipients were treated with neutralizing antibodies against tumor necrosis factor (TNF), interferon-γ (IFN-γ), or interleukin-1 (IL-1). Allograft histology as well as anti HLA-A2 antibody development and T cell proliferative responses were determined at days +5, +15, +28, and +60. Results. Allografts in untreated and anti-IFN-γ-treated recipients demonstrated full development of OAD by day +28. Allografts in anti-TNF-treated recipients showed no evidence of OAD, even at day +60. Allografts in anti-IL-1-treated recipients showed airway epithelium changes by day +28 but minimal evidence of OAD by day +60. Spleen cells from untreated and anti-IFN-γ treated recipients showed significantly higher proliferative responses to HLA-A2+ cells, compared with syngeneic recipients (negative controls). In contrast, anti-TNF and anti-IL-1-treated recipients showed significantly lower proliferative responses to HLA-A2+ cells, compared with untreated recipients. Development of anti HLA-A2 antibodies was detected in all recipients by day +15, with the exception of those treated with anti-TNF. Conclusion. Among the inflammatory cytokines, TNF seems to play a crucial role in the immunopathology of OAD developed after transplantation.",
author = "Smith, {Craig R.} and Andr{\'e}s Jaramillo and Kim Lu and Toru Higuchi and Zahid Kaleem and T. Mohanakumar",
year = "2001",
month = "11",
day = "15",
language = "English (US)",
volume = "72",
pages = "1512--1518",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor

AU - Smith, Craig R.

AU - Jaramillo, Andrés

AU - Lu, Kim

AU - Higuchi, Toru

AU - Kaleem, Zahid

AU - Mohanakumar, T.

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Background. Inflammatory cytokines play an important role in the development of experimental obliterative airway disease (OAD) after transplantation. To further determine the immunologic mechanisms associated with OAD development, we used a murine tracheal transplant model in which a single mismatched HLA-A2 transgenic molecule is indirectly recognized by the recipient CD4+ T cells and then determined whether neutralization of several inflammatory cytokines affected the development of OAD. Methods. Tracheas from HLA-A2+ C57BL/6 mice were heterotopically transplanted into C57BL/6 mice. Recipients were treated with neutralizing antibodies against tumor necrosis factor (TNF), interferon-γ (IFN-γ), or interleukin-1 (IL-1). Allograft histology as well as anti HLA-A2 antibody development and T cell proliferative responses were determined at days +5, +15, +28, and +60. Results. Allografts in untreated and anti-IFN-γ-treated recipients demonstrated full development of OAD by day +28. Allografts in anti-TNF-treated recipients showed no evidence of OAD, even at day +60. Allografts in anti-IL-1-treated recipients showed airway epithelium changes by day +28 but minimal evidence of OAD by day +60. Spleen cells from untreated and anti-IFN-γ treated recipients showed significantly higher proliferative responses to HLA-A2+ cells, compared with syngeneic recipients (negative controls). In contrast, anti-TNF and anti-IL-1-treated recipients showed significantly lower proliferative responses to HLA-A2+ cells, compared with untreated recipients. Development of anti HLA-A2 antibodies was detected in all recipients by day +15, with the exception of those treated with anti-TNF. Conclusion. Among the inflammatory cytokines, TNF seems to play a crucial role in the immunopathology of OAD developed after transplantation.

AB - Background. Inflammatory cytokines play an important role in the development of experimental obliterative airway disease (OAD) after transplantation. To further determine the immunologic mechanisms associated with OAD development, we used a murine tracheal transplant model in which a single mismatched HLA-A2 transgenic molecule is indirectly recognized by the recipient CD4+ T cells and then determined whether neutralization of several inflammatory cytokines affected the development of OAD. Methods. Tracheas from HLA-A2+ C57BL/6 mice were heterotopically transplanted into C57BL/6 mice. Recipients were treated with neutralizing antibodies against tumor necrosis factor (TNF), interferon-γ (IFN-γ), or interleukin-1 (IL-1). Allograft histology as well as anti HLA-A2 antibody development and T cell proliferative responses were determined at days +5, +15, +28, and +60. Results. Allografts in untreated and anti-IFN-γ-treated recipients demonstrated full development of OAD by day +28. Allografts in anti-TNF-treated recipients showed no evidence of OAD, even at day +60. Allografts in anti-IL-1-treated recipients showed airway epithelium changes by day +28 but minimal evidence of OAD by day +60. Spleen cells from untreated and anti-IFN-γ treated recipients showed significantly higher proliferative responses to HLA-A2+ cells, compared with syngeneic recipients (negative controls). In contrast, anti-TNF and anti-IL-1-treated recipients showed significantly lower proliferative responses to HLA-A2+ cells, compared with untreated recipients. Development of anti HLA-A2 antibodies was detected in all recipients by day +15, with the exception of those treated with anti-TNF. Conclusion. Among the inflammatory cytokines, TNF seems to play a crucial role in the immunopathology of OAD developed after transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0035890512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035890512&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 1512

EP - 1518

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -